Eurofins goes fully operational with new Central Laboratory in Singapore
Brussels/ Nantes, May 4, 2007
Eurofins announce today that their recently established Central Laboratory in Singapore is now fully operational and, operating under the Eurofins | Medinet brand, extends its network of central laboratories in Europe and the US into Asia to provide safety testing for our customers in the pharmaceutical clinical trial and drug development sector.
Eurofins commenced the construction of the facility in November 2006 and obtained its operational license from the Singapore Ministry of Health in early 2007. Located in the Synergy Building of the International Business Park, the laboratory contains state-of-the art equipment and was developed rapidly in response to strong customer interest. In this way Eurofins will continue to provide market-leading services in this fast-growing segment, supporting both our big pharmaceutical clients and the needs of smaller niche players and biotechnology companies.
“Our clients demand global analytical and testing capabilities that meet their objectives throughout all phases of drug development,” said Dr. Arnold Verbeek, CEO at Eurofins | Medinet. “Establishing the Singapore laboratory strengthens our ability to meet our customer needs worldwide while offering greater value to our bottom line.”
Eurofins | Medinet provides specialised testing in microbiology, bioanalysis, genomics, pharmacokinetics, and biomarker development using its fully accredited central laboratories in the Netherlands, USA (two labs), France and now Singapore with additional standardised partner laboratories in South Africa, India, China, Japan, and Australia.
For further information please contact your Eurofins laboratory or contact directly:
|
Robert Willis Eurofins | Medinet Tel.: +31 (0)76 5737 505 Email: Robert.Willis@eurofinsmedinet.com |
Investor Relations Tel.: +32-2-766 16 20 Email: ir@eurofins.com |
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 5,000 staff in more than 70 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext exchange in Paris (ISIN FR0000038259) and the Frankfurt (WKN 910251) Stock Exchange (Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.